The Longevity Master Stack — Epithalon, Thymalin, MOTS-c, and SS-31 Research Protocol

The four aging mechanisms — and why each needs its own intervention

Biological aging is not a single process — it is the convergence of multiple simultaneous decline trajectories that interact and amplify each other. The Longevity Master Stack targets four of the most well-characterized: telomere shortening and pineal dysregulation (Epithalon), thymic involution and immune aging (Thymalin), blunted AMPK signaling and mitochondrial biogenesis decline (MOTS-c), and cardiolipin degradation with electron transport chain dysfunction (SS-31). These four mechanisms are mechanistically independent — telomere shortening occurs even in cells with healthy mitochondria, and thymic involution occurs even with intact telomeres. Addressing all four simultaneously is the rational basis for the combination.

Epithalon: the telomere and pineal axis

Epithalon (Ala-Glu-Asp-Gly) activates telomerase to slow the telomere shortening that occurs with each cell division — one of the primary clocks of biological aging at the cellular level. It simultaneously restores pineal gland melatonin production, which coordinates the body's circadian aging response including antioxidant defense, cell cycle regulation, and immune surveillance during sleep. In Khavinsky's 30+ years of research, Epithalon-treated animal cohorts showed increased lifespan, reduced tumor incidence, and improved physiological markers of aging compared to controls. Human longitudinal data showed reduced mortality rates in elderly treated groups. Research protocol: 10mg SubQ daily for 20 consecutive days, 2-3 cycles per year. See the Epithalon research profile.

Thymalin: reversing the immunological aging clock

The thymus — the organ where T-cells mature — involutes progressively from early adulthood, producing fewer naive T-cells each year and reducing the diversity of the T-cell repertoire. This thymic aging (immunosenescence) manifests as increased infection susceptibility, reduced vaccine responses, and impaired immune surveillance of senescent and cancerous cells that allows their accumulation. Thymalin restores thymus function by normalizing T-lymphocyte activity and T-helper/suppressor balance, counteracting immunosenescence at the organ level rather than simply stimulating existing immune cells. In Khavinsky's 6-year follow-up studies in elderly cohorts, Thymalin-treated groups showed significantly reduced mortality rates and improved immune markers. Research protocol: 5-10mg SubQ or IM daily for 10 consecutive days, run concurrently with Epithalon cycles. See the Thymalin research profile.

MOTS-c: restoring the exercise signal to aging cells

MOTS-c is encoded in mitochondrial DNA and translocates to the cell nucleus under metabolic stress, activating AMPK — the master metabolic switch that drives mitochondrial biogenesis, glucose uptake, and fat oxidation. With aging, MOTS-c levels decline and AMPK becomes blunted — cells lose the ability to efficiently adapt their mitochondrial capacity to metabolic demands. MOTS-c administration restores this adaptive signal, delivering the cellular message of exercise to cells. Research protocol: 5-10mg SubQ, one injection every 5 days for 20 days (4 injections), added in the second phase of the Longevity Master Stack after SS-31 has begun membrane repair. See the MOTS-c research profile.

SS-31: repairing the engine before rebuilding capacity

SS-31 (elamipretide) binds cardiolipin on the inner mitochondrial membrane, stabilizing the respiratory supercomplex architecture that holds the electron transport chain in place. With age and oxidative stress, cardiolipin degrades, the ETC loosens, energy production efficiency drops, and ROS generation increases. SS-31 is used first in the Longevity Master Stack specifically because it repairs this structural damage before MOTS-c builds new mitochondrial capacity on top of it — building biogenesis on a compromised membrane is counterproductive. SS-31's September 2025 FDA approval for Barth syndrome validates the cardiolipin-stabilization approach. Research protocol: 4.67mg SubQ daily for 21 days, weeks 1-3 of the stack. See the SS-31 research profile.

The complete protocol sequence

Phase 1 (weeks 1-3): SS-31 4.67mg daily SubQ — repairs mitochondrial membrane structure. Phase 2 (weeks 1-4, concurrent with SS-31): Epithalon 10mg daily SubQ for 20 days and Thymalin 5-10mg daily SubQ or IM for 10 days — the Khavinsky bioregulator pair. Phase 3 (weeks 4-8): MOTS-c 5-10mg SubQ every 5 days for 20 days — builds biogenesis on the repaired foundation. NAD+ 50-150mg IM throughout all phases as the coenzyme substrate underpinning both SS-31's membrane repair and MOTS-c's biogenesis signaling. Total cycle: approximately 8-10 weeks, repeated 2-3 times per year. FOXO4-DRI (1-3mg SubQ for 3 consecutive days, once monthly) can be added as a fifth component to address senescent cell clearance — the fourth aging mechanism the core stack does not cover. See the Longevity Master Stack database entry.

Research sourcing: For research-grade Epithalon, Thymalin, MOTS-c, and SS-31 with third-party COA documentation, Peptide Hub recommends Amino Club (partner code: PEPTIDEHUB). Affiliate link — we earn a commission at no cost to you.